Iterum Therapeutics PLC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Iterum Therapeutics plc reminds shareholders to cast their votes for the upcoming Extraordinary General Meeting by February 17, 2026, with the board and ISS recommending 'FOR' all four proposals.
Iterum Therapeutics plc calls an Extraordinary General Meeting to approve critical proposals for capital raising and Nasdaq compliance, warning of potential bankruptcy if not approved.
Iterum Therapeutics plc calls for shareholder approval on critical proposals, including a significant increase in authorized share capital and an amended equity incentive plan, vital for future funding and ORLYNVAH commercialization.
Iterum Therapeutics is urging shareholders to vote in favor of a proposal at the upcoming extraordinary general meeting to allow for more efficient capital raising, critical for the company's future ahead of the PDUFA action date.
Iterum Therapeutics has adjourned its extraordinary general meeting (EGM) to October 8, 2024, to gather more shareholder proxies for a proposal outlined in its August 14, 2024 proxy statement.
DEFA14A: Iterum Therapeutics Urges Shareholders to Approve Pre-emptive Rights Waiver to Secure Future Funding
Iterum Therapeutics is urging shareholders to vote in favor of a proposal to waive pre-emptive rights on previously authorized shares, which the company says is crucial for its ability to raise capital and continue as a going concern.
DEFA14A: Iterum Therapeutics Urges Shareholders to Approve Pre-emptive Rights Waiver to Secure Future Funding
Iterum Therapeutics is urging shareholders to vote in favor of a proposal to waive pre-emptive rights on previously authorized shares, which the company says is crucial for its ability to raise capital and avoid potential insolvency.
Iterum Therapeutics has adjourned its extraordinary general meeting (EGM) to September 30, 2024, to solicit additional proxy votes for a proposal outlined in its definitive proxy statement.
Iterum Therapeutics urges shareholders to vote in favor of a proposal allowing the company to raise additional capital, warning of potential insolvency and significant shareholder value destruction if the proposal fails.
Iterum Therapeutics has adjourned its extraordinary general meeting (EGM) to September 23, 2024, to gather more shareholder proxies for a proposal outlined in its August 14, 2024 proxy statement.
Iterum Therapeutics is holding an Extraordinary General Meeting to request shareholder approval for the board to issue shares for cash without first offering them to existing shareholders, aiming to align with Nasdaq-listed peers and facilitate future capital raising.
Iterum Therapeutics plc has scheduled its Annual General Meeting for June 19, 2024, and is providing shareholders with proxy materials for voting on key proposals.
Iterum Therapeutics has scheduled its 2024 Annual General Meeting of Shareholders for June 19, 2024, to address director elections, auditor ratification, executive compensation, and other corporate matters.